Pacific Therapeutics gets US Patent Office Notice Of Allowability for Pulmonary Fibrosis treatment
Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that leads programs focused on erectile dysfunction and diseases of excessive scarring (fibrosis), announced that the US Patent Office (PO) has released a Notice Of Allowability for the Company’s patent application, Compositions and Methods for the treatment of fibroproliferative conditions.
Doug Unwin, CEO and President of the Company stated in a recent press release, “This is a huge milestone for the Company as it adds additional protection to our already issued patents for the technology in PTL-202 our lead candidate for pulmonary and of the fibrotic diseases.”
Pacific Therapeutics is developing a drug for the treatment of progressive scarring of the lung, Idiopathic Pulmonary Fibrosis (IPF) called PTL-202.
[adrotate group=”3″]
PTL-202 is a combination of the FDA approved Pentoxifylline with an amino acid and a very powerful and essential antioxidant. Positive pre-clinical results from the phase 1 clinical trial of PTL-202 will lead to future development of the drug for the treatment of fibrotic disorders including Liver Cirrhosis and Idiopathic Pulmonary Fibrosis.
Pacific Therapeutics’ design involves the reformulation of FDA approved treatments in order to increase effectiveness and patient compliance, and also to reduce adverse effects. The Company’s strategy also involves conducting the drugs clinical manufacturing, testing, and other supervisory requirements necessary to obtain marketing authorizations. This approach is meant to lessen the time, cost and risk of developing treatments by avoiding the risks related with basic investigation and using drugs with unknown toxicity and safety profiles.
